---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000103"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T08:29:11.157125+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Arvinas reports preclinical data for PROTAC BCL6 degrader ARV-393 at EHA 2025

## Summary
- Single-agent ARV-393 reduced tumor burden in peripheral blood, bone marrow, and spleen in nTFHL-AI PDX model from a post-chemo relapsed patient.
- ARV-393 monotherapy achieved ≥95% tumor growth inhibition (TGI) in two PDX models of transformed follicular lymphoma (tFL).
- Combinations with 5 small molecule inhibitors (tazemetostat, palbociclib, everolimus, acalabrutinib, venetoclax) enhanced TGI; regressions seen with 4 of 5.
- Phase 1 study (NCT06393738) enrolling relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL and AITL.
- Data suggest broad utility across NHL subtypes and support chemotherapy-free combination strategies.

## SEC filing metadata
- accession: 0001655759-25-000103
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/0001655759-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000103/arvn-20250613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000103
- JSON: https://secwatch.observer/filing/0001655759-25-000103.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.